An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs BAY 1862864 (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Bayer
- 03 Apr 2017 Planned End Date changed from 1 Sep 2019 to 30 Mar 2020.
- 03 Apr 2017 Planned primary completion date changed from 1 Sep 2019 to 30 Mar 2020.
- 11 Feb 2016 Planned End Date changed from 1 Dec 2018 to 1 Sep 2019 as per ClinicalTrials.gov record.